deltatrials
Completed PHASE1 NCT00545987

Study of a Potential Preventive Vaccine Against HIV in Healthy Volunteers

Evaluation of Local and Systemic Reactogenicity Following Serial Administration of ADVAX, a Clade C DNA Vaccine, ADVAX e/g + ADVAX p/N-t, by Ichor TriGrid™ in Vivo Electroporation to HIV-Uninfected, Healthy Volunteers

Sponsor: Aaron Diamond AIDS Research Center

Conditions HIV Infections
Interventions TriGrid™ Delivery System conventional intramuscular injection
Updated 6 times since 2017 Last updated: May 4, 2011 Started: Sep 30, 2007 Primary completion: Oct 31, 2009 Completion: Apr 30, 2011

Listed as NCT00545987, this PHASE1 trial focuses on HIV Infections and remains completed. Sponsored by Aaron Diamond AIDS Research Center, it has been updated 6 times since 2007, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Change History

6 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE1

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE1

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE1

  5. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE1

▶ Show 1 earlier version

  1. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE1

    First recorded

Sep 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Aaron Diamond AIDS Research Center
  • Bill and Melinda Gates Foundation
  • Ichor Medical Systems Incorporated
  • International AIDS Vaccine Initiative
  • Rockefeller University
Data source: Rockefeller University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • New York, United States